Differential Diagnostics of Etiology of Acute Infections
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03161951|
Recruitment Status : Enrolling by invitation
First Posted : May 22, 2017
Last Update Posted : June 27, 2018
|Condition or disease|
|Intestinal Infectious Diseases Neuroinfections|
During the study, method for diagnostics of the origin of infections (bacterial vs viral) based on the identification of activation markers of blood neutrophils and monocytes will be developed.This method will allow to make a diagnosis within an hour after blood sampling.
The expression of the following markers of activation will be studied using flow cytometry: CD11b, CD11c, CD13, CD16, CD32, CD35, CD38, CD62L, CD64, CD66b, CD88, CD284, HLA-ABC and HLA-DR.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Differential Diagnostics of Etiology of Acute Infections Based on the Analysis of Expression of Activation Markers on the Surface of Peripheral Blood Monocytes and Neutrophils.|
|Actual Study Start Date :||January 3, 2017|
|Estimated Primary Completion Date :||August 31, 2018|
|Estimated Study Completion Date :||December 31, 2018|
Patients with acute neuroinfections of bacterial and viral ethology.
Intestinal Infectious Diseases
Patients with acute intestinal infectious diseases of bacterial and viral ethology.
- Sensitivity of the diagnosis of bacterial vs viral acute infection [ Time Frame: 1 month ]Sensitivity of the diagnosis of bacterial vs viral acute infection using proposed method
- Specificity of the diagnosis of bacterial vs viral acute infection [ Time Frame: 1 month ]Specificity of the diagnosis of bacterial vs viral acute infection using proposed method
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03161951
|Study Director:||Andrei Y Hancharou, Dr||Head of the Laboratory for Immunology and Cellular Biotechnology, The Republican Research and Practical Center for Epidemiology and Microbiology|